COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,786 Articles (22,946 medRxiv, 8,840 bioRxiv)

Most recent first Previous |  Page 544: Articles 5431-5440  | Next

Divergence of wastewater SARS-CoV-2 and reported laboratory-confirmed COVID-19 incident case data coincident with wide-spread availability of at-home COVID-19 antigen tests
Boehm, A., Wolfe, M. K., White, B., Hughes, B., Duong, D.
10.1101/2023.02.09.23285716 — Posted: 2023-02-10
Social deprivation and SARS-CoV-2 testing: a population-based analysis in a highly contrasted Southern France region
Landier, J., Bassez, L., Bendiane, M. K., Chaud, P., Franke, F., Nauleau, S., Danjou, F., Malfait, P., Rebaudet, S., Gaudart, J.
10.1101/2023.02.09.23285721 — Posted: 2023-02-10
Age-specific severity of SARS-CoV-2 in February 2020 - June 2021 in the Netherlands
de Boer, P. T., van de Kassteele, J., Vos, E. R. A., van Asten, L., Dongelmans, D., van Gageldonk-Lafeber, A. B., den Hartog, G., Hofhuis, A., van der Klis, F., de Lange, D., Stoeldraijer, L., the RIVM COVID-19 epidemiology and surveillance team, , de Melker, H. E., Geubbels, E., van den Hof, S., Wallinga, J.
10.1101/2023.02.09.23285703 — Posted: 2023-02-10
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 community, highly vaccinated patients with high risk for severe disease: Evidence that both antivirals reduce the risk for disease progression and death
Paraskevis, D., Gkova, M., Mellou, K., Gerolymatos, G., Psallida, P., Gkolfinopoulou, K., Kostaki, E. G., Loukides, S., Kotanidou, A., Skoutelis, A., Thireos, L., Saroglou, G., Zografopoulos, D., Mossialos, E., Zaoutis, T., Gaga, M., Tsiodras, S., Antoniadou, A.
10.1101/2023.02.09.23285737 — Posted: 2023-02-10
Epidemiological analysis of the gender-age structure of hospitalized patients with COVID-19 and their mortality in 2020-2021.
Voronin, E. M., Khrapunova, I. A., Pechenik, A. S., Kravtsova, O. A., Chen, Z., Kostinov, M. P., Loktionova, M. N., Yakovleva, I. V., Akimkin, V. G., Brazhnik, V. A.
10.1101/2023.02.09.23285515 — Posted: 2023-02-10
Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States
Yang, F., Tran, T. N.-A., Howerton, E., Boni, M. F., Servadio, J. L.
10.1101/2023.02.08.23285658 — Posted: 2023-02-10
Sensitivity of Rapid Antigen Tests Against SARS-CoV-2 Omicron and Delta Variants
Rao, A., Westbrook, A., Bassit, L., Parsons, R., Fitts, E., Greenleaf, M., McLendon, K. B., Sullivan, J., O'Sick, W. H., Baugh, T., Bowers, H., Frank, F., Wang, E., Le, M., Frediani, J., Roychoudhury, P., Greninger, A. L., Jerris, R., Pollock, N. R., Ortlund, E., Roback, J. D., Lam, W. A., Piantadosi, A.
10.1101/2023.02.09.23285583 — Posted: 2023-02-10
Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in England
Patel, V., Levick, B., Boult, S., Gibbons, D. C., Drysdale, M., Lloyd, E. J., Singh, M., Birch, H. J.
10.1101/2023.02.08.23285654 — Posted: 2023-02-10
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
Huiberts, A. J., de Gier, B., Hoeve, C. E., de Melker, H. E., Hahne, S. J. M., den Hartog, G., van de Wijgert, J. H. H. M., van den Hof, S., Knol, M. J.
10.1101/2023.02.08.23285643 — Posted: 2023-02-10
Estimating serum cross-neutralizing responses to SARS-CoV-2 Omicron sub-lineages elicited by pre-Omicron or Omicron breakthrough infection with exposure interval compensation modeling
Miyamoto, S., Kuroda, Y., Kanno, T., Ueno, A., Shiwa-Sudo, N., Iwata-Yoshikawa, N., Sakai, Y., Nagata, N., Arashiro, T., Ainai, A., Moriyama, S., Kishida, N., Watanabe, S., Nojima, K., Seki, Y., Mizukami, T., Hasegawa, H., Ebihara, H., Fukushi, S., Takahashi, Y., Maeda, K., Suzuki, T.
10.1101/2023.02.08.23285673 — Posted: 2023-02-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).